Quality requirements for stereotactic body radiation therapy (SBRT) in multiinstitutional clinical trials
Clinical evidence have shown SBRT to be a tolerable,efficacious,and promising non-invasive therapy.Randomized prospective studies comparing surgery vs.SBRT in early-stage lung cancer are proposed to further investigate the relative survival,quality of life,and cost characteristics of these treatment paradigms.Accreditation and dosimetry requirements were carefully vetted for RTOG SBRT trials.Advanced technologies introduced since have posed additional challenges.This study provides an overview of the quality requirements including those for the recently introduced technologies.
SBRT NSCLC Surgery quality clinical trials
Y.Xiao F.Yin FM S.Kong J.Yue J.Galvin
RTOG/ACR, Philadelphia, USA;Radiation Oncology, Jefferson Medical College, Philadelphia, USA Radiation Oncology, Duke University, NC, USA Radiation Oncology, University of Michigan, Ann Arbor, USA Radiation Oncology, the Cancer Institute of New Jersey, NJ, USA
国际会议
World Congress on Medical Physics and Biomedical Engineering (2012年医学物理及生物医学工程国际会议(IFMBE))
北京
英文
2284-2287
2012-05-26(万方平台首次上网日期,不代表论文的发表时间)